Company / Cost of Revenue
ARS Pharmaceuticals, Inc. Cost of Revenue History
FY2023-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
-
FY2023
5-year range
$0 / $0
FY2023-FY2023
Trend
-
vs FY2022
Sector context
#83 of 85
Health Care
What the data says
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 2% in Health CareTop 2% of 85
▼
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $0 | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026